Literature DB >> 9476124

Catabolism of the human erythrocyte C3b/C4b receptor (CR1, CD35): vesiculation and/or proteolysis?

X Dervillez1, S Oudin, M T Libyh, T Tabary, B Reveil, F Philbert, F Bougy, M Pluot, J H Cohen.   

Abstract

Human erythrocytes (E) react by exocytosis of membrane vesicles to various stresses including the fixation of the membrane attack complex of Complement. E from normal individuals loose a notable proportion of their initial number of surface CR1 molecules during the ageing process. An acquired decrease of CR1 on E also occurs in pathological conditions such as Systemic Lupus Erythematosus or AIDS. The present study investigated whether calcium ionophore A23187 (Ca-ion) induced vesicle formation of human E in vitro is responsible for a preferential loss of CR1 as well as whether CR1 molecules at the surface of Ca-ion treated E or vesicles are: (i) functional, (ii) native or protease degraded, or (iii) more clustered than CR1 on native E. A study of E from 137 normal individuals showed that a one-hour Ca-ion induced vesicle formation preferentially removed one third of E surface CR1. Kinetic experiments suggested that all surface CR1 could be removed from E upon longer incubation times. CR1 molecules on vesicles were still able to inhibit Complement activation, and were found in larger clusters than on native E. These data suggest that a significant part of surface CR1 molecules may be removed from E by vesicle formation during the life of E in normal individuals. This phenomenon could be exacerbated in pathological conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9476124     DOI: 10.1016/s0162-3109(97)00066-0

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  6 in total

1.  Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare.

Authors:  D J Birmingham; K F Gavit; S M McCarty; C Y Yu; B H Rovin; H N Nagaraja; L A Hebert
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

2.  A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malaria.

Authors:  Ian A Cockburn; Margaret J Mackinnon; Angela O'Donnell; Stephen J Allen; Joann M Moulds; Moses Baisor; Moses Bockarie; John C Reeder; J Alexandra Rowe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-23       Impact factor: 11.205

3.  Early and extensive CD55 loss from red blood cells supports a causal role in malarial anaemia.

Authors:  Moses Gwamaka; Michal Fried; Gonzalo Domingo; Patrick E Duffy
Journal:  Malar J       Date:  2011-12-29       Impact factor: 2.979

4.  Acquired but reversible loss of erythrocyte complement receptor 1 (CR1, CD35) and its longitudinal alteration in patients with severe acute respiratory syndrome.

Authors:  F S Wang; F L Chu; L Jin; Y G Li; Z Zhang; D Xu; M Shi; H Wu; J-M Moulds
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

5.  Red blood cell complement receptor one level varies with Knops blood group, α(+)thalassaemia and age among Kenyan children.

Authors:  D H Opi; S Uyoga; E N Orori; T N Williams; J A Rowe
Journal:  Genes Immun       Date:  2016-02-04       Impact factor: 2.676

6.  Inherited and Acquired Decrease in Complement Receptor 1 (CR1) Density on Red Blood Cells Associated with High Levels of Soluble CR1 in Alzheimer's Disease.

Authors:  Rachid Mahmoudi; Sarah Feldman; Aymric Kisserli; Valérie Duret; Thierry Tabary; Laurie-Anne Bertholon; Sarah Badr; Vignon Nonnonhou; Aude Cesar; Antoine Neuraz; Jean Luc Novella; Jacques Henri Max Cohen
Journal:  Int J Mol Sci       Date:  2018-07-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.